Endo resolves FTC allegations over Lidoderm and Opana ER

Endo Pharmaceuticals yesterday settled charges brought by the Federal Trade Commission (FTC) by abandoning anti-competitive pay-for-delay agreements.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Generics

Endo International can’t stop Vasostrict generic

2 September 2021 The US District Court for the District of Delaware has ruled that one of Endo International’s pharma units cannot stop a generic of its blood pressure drug Vasostrict from being made.

Big Pharma

Endo, Impax face class-action over antitrust claims

7 June 2021 Endo International and Amneal Pharmaceuticals’ subsidiary, Impax Laboratories, have failed to prevent antitrust claims over a patent settlement from going to trial.

Americas

Endo pays $2.3m to settle states antitrust claims

22 July 2019 Ireland-headquartered Endo Pharmaceuticals agreed to pay $2.3 million to 18 states late last week, settling allegations that the drugmaker paid a competitor to keep a generic version of pain relief drug Lidoderm off the market.

More features

Killing the golden goose of US drug innovation (Part II): Drug pricing myths

Former pharma GC brings in-house perspective to McGuireWoods

Sandoz eyes US biosimilar launch as Regeneron settles

Killing the golden goose of US drug innovation (Part I): Follow the money

Buchalter brings in new partner to head up medtech

Trump’s march-in rights threat: Why pharma is rethinking collaborations

UK gets new IP minister following cabinet reshuffle

Barnes & Thornburg reveals five new IP leaders

Endo resolves FTC allegations over Lidoderm and Opana ER

More on this story

Editor's picks

Editor's picks

More features